COTA

COTA improves clinical outcomes and reduces wasteful spend in oncology through precise classification of illness and a smarter use of data. We empower oncologists with actionable insights, enable alternative payment models, create national outcomes benchmarks, accelerate drug discovery and approval, and empower patients to make better decisions for their care.

 
Related News
Cota Founder and Executive Chairman to Present at the Vatican’s Unite to Cure Conference
04.27.18
Cota Inc., a real-world data and analytics company bridging precision medicine to population health, today announced its founder and executive chairman, Andrew Pecora, M.D., will speak today, April 27 at the Fourth International Vatican Conference, Unite to Cure: A Global Health Care Initiative, which is being held from April 26-28 at the Aula Nuova del Sinodo in Vatican City. The event will build on the current global health care movement and unite world leaders across all disciplines to engage in powerful conversations about how science, technology and 21st century medicine will impact culture and society. Read Full Release
HIMSS18: Interview with Stuart Goldberg, M.D. | Cota | Precision Payment
03.29.18
On this episode we talk with Stuart Goldberg, MD, Chief Scientific Officer at Cota. Dr. Goldberg tells us all about Cota’s physician-led journey to organize and classify real-world evidence about every type of cancer. This effort led to something they call the Cota Nodal Address (CNA), and it’s enabling health systems to get very specific about the types of patients they’re treating, the costs associated with them, and the outcomes being achieved. This apples-to-apples comparison allows Cota to identify variation and address it in ways that are beneficial to the provider, payer and patient. It enables a concept Dr. Goldberg calls “Precision Payment”, which in turn enables proper bundled payment design, and precision medicine. Read Full Release
Cota Announces $40 Million Series C Financing to Advance its Cota Nodal Address™ Classification System and Real-World Evidence and Analytics Platforms
02.21.18
Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE: IQV) with major participation by EW Healthcare Partners. Cota will leverage this funding to scale its solutions across healthcare providers, payers and life sciences companies. The funding will also advance its proprietary Cota Nodal Address™ (CNA) system, a powerful and unique precision disease classification system built on its comprehensive real-world data set. Memorial Sloan Kettering Cancer Center also participated in the round, along with existing Cota investors which include, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings. Read Full Release
COTA’s Pecora named Executive of the Year at NJBIZ Healthcare Heroes
06.21.17
Dr. Andrew Pecora said he was honored and humbled when he received the Health Care Executive of the Year award at the NJBIZ Healthcare Heroes awards event Tuesday. Pecora, the president of physician services and chief innovation officer at Hackensack Meridian Health, was quick to recognize his colleagues in the crowd as well as the other honorees at the event. Read Full Release
Hackensack Meridian Health taps IBM Watson for help on cancer treatments
06.05.17
IBM Watson Health, Cota Healthcare and Hackensack Meridian Health are partnering to test clinical decision support in cancer treatment, a pilot that will draw on Cota's precision-medicine database and Watson Health's artificial intelligence-enabled evidence-based recommendations. Read Full Release
COTA, IBM Watson teaming up for pilot program at Hackensack Meridian
05.10.17
Imagine waiting for your diagnosis. The doctor walks in and says, “Well, I just consulted with everyone on the planet Earth over the last 30 years to see how they took care of people like you, and then I looked at a database that precisely looked at people who have exactly what you have, and are exactly like you, and this is what I have learned in the past five minutes, and this is why I am going to recommend this treatment.” Read Full Release
COTA Collaborates with Novartis Pharmaceuticals Corporation
03.27.17
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release
Introducing Cota OCM™—A Solution for Practices Moving to Value-based Programs
02.10.17
Over the last year, our team at Cota has worked closely with providers and CMS—preparing for the eventual move to value-based payment under MACRA by studying the complexities of the law and building an OCM-specific technology solution on top of our CNA Guided Care™ platform. To address the obvious policy question up front: While the new administration has already planned or implemented sweeping changes across other areas, all indications (including these comments from former CMS head Andy Slavitt) point to Alternative Payment Models (APMs) and value-based payments sticking around for the long haul. In this post, we want to share what we’ve learned so far and officially announce Cota’s new technology solution specifically designed to help providers address the challenges and opportunities during this exciting time in the move value-based healthcare. Jump straight to the Cota OCM product announcement here. Read Full Release
BMP Invests in COTA
12.20.16
Boston Millennia Partners Invests in Cota, Inc. Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release
PE Hub Network on BMP invests in Cota
12.15.16
BOSTON–(BUSINESS WIRE)–December 15, 2016–Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release